Condition: Metastatic Esophageal Adenocarcinoma · Metastatic Esophageal Squamous Cell Carcinoma · Metastatic Gastroesophageal Junction Adenocarcinoma · Sponsor: National Cancer Institute (NCI)
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | — |
| Stanford Cancer Institute Palo Alto | Palo Alto, California, United States | — |
| The Medical Center of Aurora | Aurora, Colorado, United States | — |
| Boulder Community Foothills Hospital | Boulder, Colorado, United States | — |
| Penrose-Saint Francis Healthcare | Colorado Springs, Colorado, United States | — |
| AdventHealth Porter | Denver, Colorado, United States | — |
| Presbyterian - Saint Lukes Medical Center - Health One | Denver, Colorado, United States | — |
| Saint Joseph Hospital - Cancer Centers of Colorado | Denver, Colorado, United States | — |
| Rose Medical Center | Denver, Colorado, United States | — |
| Western States Cancer Research NCORP | Denver, Colorado, United States | — |
| Swedish Medical Center | Englewood, Colorado, United States | — |
| Saint Mary's Hospital and Regional Medical Center | Grand Junction, Colorado, United States | — |
+ 220 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.